These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20332351)

  • 1. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
    Buse JB; Sesti G; Schmidt WE; Montanya E; Chang CT; Xu Y; Blonde L; Rosenstock J;
    Diabetes Care; 2010 Jun; 33(6):1300-3. PubMed ID: 20332351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
    Polster M; Zanutto E; McDonald S; Conner C; Hammer M
    J Med Econ; 2010; 13(4):655-61. PubMed ID: 21034377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
    Lecube A; Bueno M; Suárez X
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
    Buse JB; Nauck M; Forst T; Sheu WH; Shenouda SK; Heilmann CR; Hoogwerf BJ; Gao A; Boardman MK; Fineman M; Porter L; Schernthaner G
    Lancet; 2013 Jan; 381(9861):117-24. PubMed ID: 23141817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.
    Twigg SM; Daja MM; O'leary BA; Adena MA
    J Diabetes; 2016 Nov; 8(6):866-876. PubMed ID: 26729046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
    Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
    Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
    Forti A; Garcia EG; Yu MB; Jimenez MC; Brodows RG; Oliveira JH
    Curr Med Res Opin; 2008 Sep; 24(9):2437-47. PubMed ID: 18662495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M; Bouchard JR; Langer J
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
    Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
    Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG
    MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
    Pencek R; Blickensderfer A; Li Y; Brunell SC; Anderson PW
    Postgrad Med; 2012 Jul; 124(4):21-32. PubMed ID: 22913891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.